Excalipoint Therapeutics

Executive Summary

Excalipoint Therapeutics is a Hong Kong-based preclinical oncology company pioneering proteomics-driven targeted protein degradation (TPD). Its platform identifies novel disease-causing proteins in cancer and designs selective small-molecule degraders, addressing targets beyond traditional inhibition. Leveraging proteomic profiling, the company aims to expand the druggable space and overcome resistance mechanisms. Founded in 2020, Excalipoint is privately held and operates in stealth with limited disclosed data. Its approach aligns with the growing TPD field, offering potential for first-in-class therapies. However, as a preclinical entity, it faces high technical and regulatory risks. The company is likely seeking Series A financing to advance lead programs toward IND-enabling studies.

Upcoming Catalysts (preview)

• Q3 2026Lead Program Preclinical Proof-of-Concept Data40% success
• Q2 2026Series A Financing Announcement60% success
• Q4 2026Partnership or Licensing Deal for Platform Technology30% success